MARKET

ZLAB

ZLAB

Zai Lab
NASDAQ

Real-time Quotes | Nasdaq Last Sale

43.06
+0.03
+0.07%
After Hours: 43.06 0 0.00% 16:55 12/13 EST
OPEN
43.23
PREV CLOSE
43.03
HIGH
43.25
LOW
42.55
VOLUME
236.63K
TURNOVER
--
52 WEEK HIGH
43.29
52 WEEK LOW
20.22
MARKET CAP
2.85B
P/E (TTM)
-16.5762
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ZLAB and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ZLAB News

  • The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer
  • Benzinga.1d ago
  • The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint
  • Benzinga.3d ago
  • The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares
  • Benzinga.4d ago
  • Hedge Funds Have Never Been This Bullish On Zai Lab Limited (ZLAB)
  • Insider Monkey.6d ago

More

Industry

Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Name
Price
%Change

About ZLAB

Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.
More

Webull offers Zai Lab Ltd (ZLAB) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.